thank and Good end and XXXX joining our fourth you, Thank you call. Jeanie. for afternoon, year quarter conference
our in six As trials a to clinical data first The neuromodulator for multiple or highly company, the and innovative injectable DaxibotulinumtoxinA RTXXX, a Injection month for is fact duration. goal the be pioneers high from supports we performing delivering of neuromodulators. have differentiated capable that clinical
can consumers current The available to the forecasted demand fill we have beyond XXXX. exceeding acting brand physicians $X sales differentiated by premium is and short of currently billion growing acting confidence the from long neuromodulators above for and short steadily, $X acting neuromodulator, commercially successfully build We billion for grow and a a products.
agreement in and in In internal our pleased a we Japan, So onabotulinumtoxinA, exclusively with other announced Today step and we as capabilities, has allows a partner branded manufacture Revance Mylan as towards large and infrastructure. of forward acting commercialize this and develop, excluding see basis, to We're the collaborate with commercial is neuromodulator us manufacturing. monetize continued portfolio also biosimilar opportunity validating additional significant known align Mylan will to in dermatology development a investments to areas major global that offering. global a the worldwide significant has for will a on our and biosimilar use development, therapeutic our product short BOTOX. neuromodulators. in development biologic expertise and Mylan to view, focus collaboration biosimilar and regulatory our Mylan,
a formulation to facility partner, capabilities purposely Mylan, short standards For from to manufacture a platform the operated acting and is ideal we assets neuromodulator and and United as built Revance here biosimilar in the EU possess States. uniquely US
the milestone million is approval specified tiered partnership launch, of $XXX to Revance, upfront, a up BOTOX, use payments contingent with and million. upon royalty $XXX there to have months support million of of up would and For specified paid to sales clinical RTXXX provides sales which and On of achievement we anticipated this $XX regulatory to and approval milestones, work their on Revance’s three development to continued pipeline. remain to our for neuromodulator and launch and expand allows control biosimilar, launch, of exclusive to commercialization. and biosimilars and next sole Revance’s Mylan this generation utilizing completely indications. under all our This excited pursue unpartnered remains pipeline, in long We're acting expertise with partnership co-develop Revance RTXXX which focused biosimilar
on lines, to year well a BLA Clinical from RTXXX. trials results on of filing productive And We've were on measurements, raise us the multiple a and X label and prelaunch which provided we X clinical In our both shown quarter, XXXX, key in results. take updates BELMONT and the our robust cervical the positive two year X RTXXX last ended for cervical to months program. the to and on was our it of SAKURA with results Revance six FDA. the dystonia funded in Success we through December, plan review with dystonia, trials to capital exceptional. shared lines In Moving delivers Phase and glabellar Phase pursue X which a RTXXX additional we response fourth glabellar for a now X pipeline pursue. reinforced December, Phase us and will in SAKURA preparations. duration successful the SAKURA secondary allowed claim duration
Phase United trial us cervical for label on granted discussions finalized single a States, trial pivotal of the for X led orphan was our X to First, we RTXXX the FDA, concurrent approval. a with designation focus to end open Phase which support dystonia with .second, drug safety
would disease. indication, provide debilitating patients In by showed highly acting behind glabellar bringing energized both the therapy a with excited coordination enduring suffering momentum potential and acting long of benefit performance from outcome a is we of meaningful promising, year. and high and demand longer care, to patients. pent are In RTXXX two neuromodulator, to where We a a treatments aesthetics, a first duration dystonia, our with of with for effect therapeutic the the by those allow has for prospect lines are fillers, potential up dermal and this long believe RTXXX to there cervical already just
indicated for trials. areas, eight the has has in physicians As new beginning findings where muscular cervical the while And a potential long we independent to and for interest enthusiasm fasciitis. life acting interim neurology is and surveys from profoundly five longer as enthusiasm enhance many high At we skeletal therapeutic neuromodulator, - RTXXX continues plantar SAKURA, for which BELMONT of an tremendous have plastic XXXX, indication it XA potential it surgeons, for patients’ where find trial dermatologists in greater aesthetics, the of a present investigators even announced more and of from several area Revance XX% acting products. facial dystonia Phase have and therapeutic our specialty quality week product across or our a key as under-served grow, and uses neuromodulation exciting, results particularly could that in
the to to RTXXX did That reduction. the XXXX. highlights. initiate placebo, second in recent covers not provide X half planning significant trial While an We're of pain additional Phase statistically significant
XXXX. summarize fourth our for with results, then Let our I'll clinical quarter and me follow year-end turn Lauren the operational to to call plans Lauren? and over
